Asciminib (Scemblix®) is an orally administered, small molecule, selective allosteric inhibitor
that targets the myristoyl pocket of the BCR-ABL1 tyrosine kinase and is being developed by …

Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is a neoplastic
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …

Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used
for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

Chronic myeloid leukemia (CML) is one of the most common leukemias occurring in the
adult population. The course of CML is divided into three phases: the chronic phase, the …

Ponatinib, the only third‐generation pan‐BCR:: ABL1 inhibitor with activity against all known
BCR:: ABL1 mutations including T315I, has demonstrated deep and durable responses in …

Leukemia is a hematological malignancy associated with the uncontrolled proliferation of
mutant progenitors, suppressing the production of normal blood cells. Current treatments …

Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for
measuring gene expression, doing clonality assays and detecting hot spot mutations. In …

Chronic myeloid leukemia (CML) is driven by a translocation event between chromosomes 9
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …

BCR-ABL1 is a fusion protein as a result of a unique chromosomal translocation (producing
the so-called Philadelphia chromosome) that serves as a clinical biomarker primarily for …